Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial.

[1]  H. Mirzaei,et al.  Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status , 2018, International journal of cancer.

[2]  G. Calaf,et al.  Curcumin and paclitaxel induce cell death in breast cancer cell lines. , 2018, Oncology reports.

[3]  F. Cantrell,et al.  Death associated with intravenous turmeric (Curcumin) preparation , 2018, Clinical toxicology.

[4]  Javad Zavar Reza,et al.  Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy , 2018, Journal of Nanobiotechnology.

[5]  T. Decker,et al.  A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO) , 2017, BMC Cancer.

[6]  Ling Zhao,et al.  Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review). , 2017, Oncology reports.

[7]  G. Calaf,et al.  Effect of curcumin and paclitaxel on breast carcinogenesis. , 2016, International journal of oncology.

[8]  A. Gaikwad,et al.  Curcumin as an adjuvant to breast cancer treatment. , 2015, Anti-cancer agents in medicinal chemistry.

[9]  Ifeanyi D. Nwachukwu,et al.  Curcumin and cancer: barriers to obtaining a health claim. , 2015, Nutrition reviews.

[10]  R. Wu,et al.  Curcumin Modulates miR‐19/PTEN/AKT/p53 Axis to Suppress Bisphenol A‐induced MCF‐7 Breast Cancer Cell Proliferation , 2014, Phytotherapy research : PTR.

[11]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Zihui Xu,et al.  Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  Rui Liu,et al.  Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling , 2014, Archives of pharmacal research.

[14]  Zhidong Lv,et al.  Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. , 2014, International journal of clinical and experimental pathology.

[15]  Abraham H. Abouzeid,et al.  Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. , 2014, International journal of pharmaceutics.

[16]  Abraham H. Abouzeid,et al.  Transferrin-Targeted Polymeric Micelles Co-loaded with Curcumin and Paclitaxel: Efficient Killing of Paclitaxel-Resistant Cancer Cells , 2014, Pharmaceutical Research.

[17]  B. Aggarwal,et al.  Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers , 2013, British journal of pharmacology.

[18]  Fatih Kocabaş,et al.  Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. , 2013, Molecular pharmaceutics.

[19]  Zhiwei Chen,et al.  The Effect of Curcumin on Breast Cancer Cells , 2013, Journal of breast cancer.

[20]  Ping Wang,et al.  [Study on curcumin-induced apoptosis in ovarian cancer resistant cell lines COC1/DDP]. , 2012, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition.

[21]  E. Sreekumar,et al.  Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer , 2011, Oncogene.

[22]  Jen-kun Lin,et al.  1,2,3,4,6-penta-O-galloyl-β-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. , 2011, Journal of agricultural and food chemistry.

[23]  R. J. Anto,et al.  Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. , 2011, The international journal of biochemistry & cell biology.

[24]  Jung-Hyun Park,et al.  Anti-carcinogenic properties of curcumin on colorectal cancer. , 2010, World journal of gastrointestinal oncology.

[25]  Faisal T Thayyullathil,et al.  Modulation of curcumin-induced Akt phosphorylation and apoptosis by PI3K inhibitor in MCF-7 cells. , 2010, Biochemical and biophysical research communications.

[26]  J. Price,et al.  Curcumin Suppresses the Paclitaxel‐Induced Nuclear Factor‐κB in Breast Cancer Cells and Potentiates the Growth Inhibitory Effect of Paclitaxel in a Breast Cancer Nude Mice Model , 2009, The breast journal.

[27]  S. Ganta,et al.  Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. , 2009, Molecular pharmaceutics.

[28]  H. Gómez,et al.  Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Aggarwal,et al.  Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. , 2008, Cancer letters.

[30]  S. Vareed,et al.  Pharmacokinetics of Curcumin Conjugate Metabolites in Healthy Human Subjects , 2008, Cancer Epidemiology Biomarkers & Prevention.

[31]  Robert A Newman,et al.  Bioavailability of curcumin: problems and promises. , 2007, Molecular pharmaceutics.

[32]  H. Mukhtar,et al.  Curcumin for chemoprevention of colon cancer. , 2007, Cancer letters.

[33]  K. Gelmon,et al.  The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer , 2007, Cancer.

[34]  F. Campbell,et al.  Chemopreventive properties of curcumin. , 2005, Future oncology.

[35]  Sanjeev Banerjee,et al.  Curcumin Suppresses the Paclitaxel-Induced Nuclear Factor-κB Pathway in Breast Cancer Cells and Inhibits Lung Metastasis of Human Breast Cancer in Nude Mice , 2005, Clinical Cancer Research.

[36]  Claudia Fruijtier-Pölloth.  Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. , 2005, Toxicology.

[37]  M. Diederich,et al.  Chemopreventive and therapeutic effects of curcumin. , 2005, Cancer letters.

[38]  M. Pirmohamed,et al.  Phase I Clinical Trial of Oral Curcumin , 2004, Clinical Cancer Research.

[39]  R. Kudo,et al.  Mechanisms of Paclitaxel-Induced Apoptosis in an Ovarian Cancer Cell Line and Its Paclitaxel-Resistant Clone , 2004, Oncology.

[40]  B. Aggarwal,et al.  Nuclear factor-kappa B and cancer: its role in prevention and therapy. , 2002, Biochemical pharmacology.

[41]  M. Wientjes,et al.  Kinetics of P-glycoprotein-mediated efflux of paclitaxel. , 2001, The Journal of pharmacology and experimental therapeutics.

[42]  Mi-Sung Kim,et al.  Inhibition of Invasion and Induction of apoptosis by curcumin in H-ras-Transformed MCF10A human breast epithelial cells , 2001, Archives of pharmacal research.

[43]  S. Jee,et al.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. , 2001, Anticancer research.

[44]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[45]  A. Tutt,et al.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.

[46]  M. Wolzt,et al.  Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. , 2015, International journal of clinical pharmacology and therapeutics.

[47]  W. Gradishar,et al.  A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. , 2013, European journal of cancer.

[48]  C. China Pharmacopoeia,et al.  Pharmacopoeia of the People's Republic of China , 2010 .

[49]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[50]  V. Menon,et al.  Antioxidant and anti-inflammatory properties of curcumin. , 2007, Advances in experimental medicine and biology.

[51]  Ricky A. Sharma,et al.  Pharmacokinetics and pharmacodynamics of curcumin. , 2007, Advances in experimental medicine and biology.

[52]  D. Karnofsky.  The clinical evaluation of chemotherapeutic agents in cancer , 1949 .